Detailed entry information

Protein Information (annotations from UniProt)

Database IDHIV0001623
UniProt IDQ9UJU2
Primary gene name(s)LEF1
Synonym gene name(s)unknown
Protein nameLymphoid enhancer-binding factor 1
Protein functionParticipates in the Wnt signaling pathway. Activates transcription of target genes in the presence of CTNNB1 and EP300. May play a role in hair cell differentiation and follicle morphogenesis. TLE1, TLE2, TLE3 and TLE4 repress transactivation mediated by LEF1 and CTNNB1. Regulates T-cell receptor alpha enhancer function. Binds DNA in a sequence-specific manner. PIAG antagonizes both Wnt-dependent and Wnt-independent activation by LEF1, By similarity. Isoform 3 lacks the CTNNB1 interaction domain and may be an antagonist for Wnt signaling. Isoform 5 transcriptionally activates the fibronectin promoter, binds to and represses transcription from the E-cadherin promoter in a CTNNB1-independent manner, and is involved in reducing cellular aggregation and increasing cell migration of pancreatic cancer cells. Isoform 1 transcriptionally activates MYC and CCND1 expression and enhances proliferation of pancreatic tumor cells. {ECO:0000250, ECO:0000269|PubMed:11266540, ECO:0000269|PubMed:19653274, ECO:0000269|PubMed:2010090}.
Subcellular locationNucleus {ECO:0000255|PROSITE-ProRule:PRU00267}. Note=Found in nuclear bodies upon PIASG binding. {ECO:0000250}.
ECO codeClick here for more information.
Amino acid sequence
FASTA format: Q9UJU2
Gene Ontology
(Biological Process)
Complete annatation
alpha-beta T cell differentiation [GO:0046632];
anatomical structure regression [GO:0060033];
apoptotic process involved in morphogenesis [GO:0060561];
apoptotic process involved in patterning of blood vessels [GO:1902262];
B cell proliferation [GO:0042100];
beta-catenin-TCF complex assembly [GO:1904837];
BMP signaling pathway [GO:0030509];
canonical Wnt signaling pathway [GO:0060070];
cell chemotaxis [GO:0060326];
cellular response to cytokine stimulus [GO:0071345];
cellular response to interleukin-4 [GO:0071353];
chorio-allantoic fusion [GO:0060710];
dentate gyrus development [GO:0021542];
embryonic limb morphogenesis [GO:0030326];
epithelial to mesenchymal transition [GO:0001837];
eye pigmentation [GO:0048069];
face morphogenesis [GO:0060325];
forebrain neuroblast division [GO:0021873];
forebrain neuron differentiation [GO:0021879];
forebrain radial glial cell differentiation [GO:0021861];
formation of radial glial scaffolds [GO:0021943];
histone H3 acetylation [GO:0043966];
histone H4 acetylation [GO:0043967];
hypothalamus development [GO:0021854];
mammary gland development [GO:0030879];
muscle fiber development [GO:0048747];
negative regulation of apoptotic process [GO:0043066];
negative regulation of apoptotic process in bone marrow [GO:0071866];
negative regulation of canonical Wnt signaling pathway [GO:0090090];
negative regulation of cell-cell adhesion [GO:0022408];
negative regulation of cysteine-type endopeptidase activity involved in apoptotic process [GO:0043154];
negative regulation of DNA binding [GO:0043392];
negative regulation of estrogen receptor binding [GO:0071899];
negative regulation of interleukin-13 production [GO:0032696];
negative regulation of interleukin-4 production [GO:0032713];
negative regulation of interleukin-5 production [GO:0032714];
negative regulation of striated muscle tissue development [GO:0045843];
negative regulation of transcription, DNA-templated [GO:0045892];
negative regulation of transcription from RNA polymerase II promoter [GO:0000122];
neural crest cell migration [GO:0001755];
neutrophil differentiation [GO:0030223];
odontoblast differentiation [GO:0071895];
odontogenesis of dentin-containing tooth [GO:0042475];
osteoblast differentiation [GO:0001649];
palate development [GO:0060021];
paraxial mesoderm formation [GO:0048341];
patterning of blood vessels [GO:0001569];
positive regulation by host of viral transcription [GO:0043923];
positive regulation of cell-cell adhesion [GO:0022409];
positive regulation of cell cycle process [GO:0090068];
positive regulation of cell growth [GO:0030307];
positive regulation of cell migration [GO:0030335];
positive regulation of cell proliferation [GO:0008284];
positive regulation of cell proliferation in bone marrow [GO:0071864];
positive regulation of epithelial to mesenchymal transition [GO:0010718];
positive regulation of gene expression [GO:0010628];
positive regulation of granulocyte differentiation [GO:0030854];
positive regulation of transcription, DNA-templated [GO:0045893];
positive regulation of transcription from RNA polymerase II promoter [GO:0045944];
regulation of cell-cell adhesion [GO:0022407];
regulation of striated muscle tissue development [GO:0016202];
sensory perception of taste [GO:0050909];
somitogenesis [GO:0001756];
sprouting angiogenesis [GO:0002040];
T cell receptor V(DJ recombination [GO:0033153];
T-helper 1 cell differentiation [GO:0045063];
tongue development [GO:0043586];
trachea gland development [GO:0061153];
transcription from RNA polymerase II promoter [GO:0006366];
Wnt signaling pathway [GO:0016055];
Wnt signaling pathway, calcium modulating pathway [GO:0007223]
Gene Ontology
(Molecular Function)
Complete annatation
armadillo repeat domain binding [GO:0070016];
beta-catenin binding [GO:0008013];
C2H2 zinc finger domain binding [GO:0070742];
chromatin binding [GO:0003682];
cysteine-type endopeptidase inhibitor activity involved in apoptotic process [GO:0043027];
DNA binding [GO:0003677];
DNA binding, bending [GO:0008301];
enhancer binding [GO:0035326];
estrogen receptor activity [GO:0030284];
estrogen receptor binding [GO:0030331];
gamma-catenin binding [GO:0045295];
histone binding [GO:0042393];
histone deacetylase binding [GO:0042826];
RNA polymerase II core promoter proximal region sequence-specific DNA binding [GO:0000978];
RNA polymerase II regulatory region sequence-specific DNA binding [GO:0000977];
sequence-specific DNA binding [GO:0043565];
transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding [GO:0001077];
transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding [GO:0001228];
transcription factor activity, RNA polymerase II distal enhancer sequence-specific binding [GO:0003705];
transcription factor activity, sequence-specific DNA binding [GO:0003700];
transcription regulatory region DNA binding [GO:0044212]
Gene Ontology
(Cellular Component)
Complete annatation
beta-catenin-TCF complex [GO:1990907];
cytoplasm [GO:0005737];
nucleoplasm [GO:0005654];
nucleus [GO:0005634];
protein-DNA complex [GO:0032993];
transcription factor complex [GO:0005667]
Protein-protein interaction119354
Phylogenetic treeQ9UJU2
HIV replication factor status Zhou et al., Cell. Host. Microbe., 2008
Brass et al., Science, 2008
Smith et al., J. Immunol, 2010
gene status
Lu et al., J. Virol., 2011
      Folds changes 8h: unknown; Folds changes 16h: unknown; Tested: unknown;
Schoggins JW and Rice CM, Curr. Opin. Virol., 2011
      Targeted viruses: unknown
      Viral life cycle: unknown
      Mechanism related to antiviral activity: unknown
Anti-viral restriction factor Liu et al., Retrovirology, 2011
      unknown (Triplicates)

Gene Expression Profile       top

            Up-regulated;            Down-regulated

For brief introduction to each study, please go to the help page.

Gene expression during HIV latency

(1). Mohammadi et al., PLoS Pathog., 2014

Differentially expressed transcripts (Pairwise) during latency and subsequent viral reactivation using several agents - Primary CD4+ T-cell based model

DMSO: Dimethyl suloxyde (negative control) - 0.0033% final
SAHA: Vorinostat (Histone deacetylase inhibitor) - 0.5 μM
CD3: TCR Stimulation by IL-2+ antiCD3/anti-CD28 antibodies
IL7: Interleukin-7 based stimulation
DISU: Disulfiram (alcohol dehydrogenase inhibitor) - 0.5 μM
AZA: 5-azacytidine (AZA; DNA methylation inhibitor) - 1 μM
Experimental Condition Log2 Fold Change P value Adjusted P value
AZA vs. CD3-1.232014322014240.0002056462424824270.00090761351879799
AZA vs. DISU-0.3259110739299610.3544879997017250.889998685460326
AZA vs. IL7-0.1230324846834970.7503960161742710.999311006273513
AZA vs. SAHA-0.3656439359044640.3592355745691080.72744721266184
DISU vs. CD30.8922436603569130.01447468856250560.0394916661341554
DISU vs. IL70.195536852881080.5778578091142520.86535565068945
DISU vs. SAHA-0.04082578581575680.911039916339550.979824632780515
DMSO vs. AZA0.01576014683333540.9676756201469271
DMSO vs. CD31.225231543223280.0001563429782031060.000668741330672852
DMSO vs. DISU0.3367415294525070.3350686089701650.83531578778832
DMSO vs. IL7-0.1300202178102150.7366333513680450.946615614344325
DMSO vs. SAHA-0.3878151322124730.3287662910964570.682594762802673
HIV vs. Mock in Activation-0.6063363817896540.3314850659565660.999983755607037
HIV vs. Mock in Latency-0.8939578423071540.0003158095374768970.0261566646589381
IL7 vs. CD31.121357181904840.0006978520957462430.00312128327572199
SAHA vs. CD30.8373812204168560.01873776985242410.0436172677905517
SAHA vs. IL7-0.2501501225429450.52634229498660.747990713650914
(2). Iglesias-Ussel et al., J. Virol., 2013

Up and Downregulated transcripts during Latency (Latently infected CD4+ T cells vs Uninfected)- Primary CD4+Tcell based model
Log2 Fold Change P Value
unknown unknown

Gene expression during HIV infection and replication

(1). Imbeault et al., PloS Pathog., 2012

Transcriptomic profiling of HIV-1 infected CD4+ T cells - Primary CD4+ T cells
Experiment type Log2 Fold Change P Value Adjusted P Value
Infected vs. Mock unknown unknown unknown
Infected vs. Bystander unknown unknown unknown
(2). Lefebvre et al., J. Virol., 2011

Transcriptome analysis of T-cell line (Sup T1)
Log2 Fold Change unknown
(3). Li et al., J. Immunol., 2013

Lymphatic tissue
Acute Fold Change Acute P Value Asymt Fold Change Asypt P Value AIDS Fold Change AIDS P Value
-1.3 0.131319001 -1.7 0.001181839 -2.6 8.03E-05
(4). Chang et al., MBio., 2011

Transcriptome analysis of T-cell line (Sup T1)

Derived from Sherrill-Mix et al., BMC Retrovirol., 2015 cross validation
Up-regulated (True) FALSE
(5). Sherrill-Mix et al., BMC Retrovirol., 2015

Deep RNA-seq analysis of primary human T cell infected with low passage HIV isolate HIV89.6 - Primary CD4+ T cell based
Test Status Log2 Fold Change P Value
OK -0.962905 0.000305467
(6). Rotger et al., PLoS Pathog., 2010

Genome-wide mRNA expression of CD4+ T cells from HIV-infected patient
(Genes differentially expressed (at adjusted p<0.01) according to the empirical Bayes approach)
Log2 Fold Change P Value
unknown unknown

Proteomic/Transcriptomics studies indicating differentially expressed genes mediated by HIV

(1). Greenwood et al., Elife, 2016

Activated (CD3/CD28) Primary human CD4+ T cells infected with pNL4-3-dE-EGFP. The table shows the complete (unfiltered) TMT (tandem mass tag)-based proteomic time course dataset
6 h 24 h 48 h 72 h RTi
0.819 0.836 0.581 0.527 1.362
(2). Navare et al., Virology, 2012

SUP-T1 cell line
FC-4hpi P-value FC-8hpi P-value FC-20hpi P-value Category
unknown unknown unknown unknown unknown unknown unknown
(3). Hyrcza et al., J. Virolo., 2007

Primary human CD4+ and CD8+ T Cells
Affymetrix Prob ID Fold Change In CD8? Category
221558_s_at 1.79 No downregulated in CD8+ cells

Protein Overview       top

Drug-protein Interaction       (annotations from DrugBank)      top

not found

Protein Secondary Structure       (annotations from PDB)      top

not found

HIV-1 Interaction       (annotations from NCBI HIV-1 Interaction Database)      top

HIV Partner Interaction Type PubMed
Tat downregulates 21744004

Metabolic/Signalling Pathway       (annotations from KEGG database)      top

Pathway Accession Number Description
hsa04310 Wnt signaling pathway - Homo sapiens (human)
hsa04390 Hippo signaling pathway - Homo sapiens (human)
hsa04520 Adherens junction - Homo sapiens (human)
hsa04916 Melanogenesis - Homo sapiens (human)
hsa05200 Pathways in cancer - Homo sapiens (human)
hsa05210 Colorectal cancer - Homo sapiens (human)
hsa05213 Endometrial cancer - Homo sapiens (human)
hsa05215 Prostate cancer - Homo sapiens (human)
hsa05216 Thyroid cancer - Homo sapiens (human)
hsa05217 Basal cell carcinoma - Homo sapiens (human)
hsa05221 Acute myeloid leukemia - Homo sapiens (human)
hsa05224 Breast cancer - Homo sapiens (human)
hsa05412 Arrhythmogenic right ventricular cardiomyopathy (ARVC) - Homo sapiens (human)